A Framework for the Fair Pricing of Medicines

Mike Paulden ()
Additional contact information
Mike Paulden: University of Alberta

PharmacoEconomics, 2024, vol. 42, issue 2, No 3, 145-164

Abstract: Abstract As high-cost medicines put increasing pressure on public health care budgets, the need to identify ‘fair’ prices for medicines has never been greater. This paper proposes a framework, built upon fundamental economic principles, that allows for the consideration of ‘fair’ prices for medicines. The framework incorporates key considerations from conventional supply-side and demand-side approaches for specifying a cost-effectiveness ‘threshold’, including the health opportunity cost borne by other patients ( $$k$$ k ) and society’s willingness to pay for marginal improvements in population health ( $$v$$ v ). The costs incurred by manufacturers in developing and supplying new medicines are also considered, as are the incentives for manufacturers to strategically price up to any common price per unit of benefit (cost-effectiveness ‘threshold’) specified by the payer. The framework finds that, at any ‘fair’ price, a medicine’s dynamically calculated incremental cost-effectiveness ratio (ICER) lies below $$k$$ k . When pricing medicines collectively, the framework finds that a common price below $$k$$ k is required to maximize population health (consumer surplus) or to maximize total welfare (consumer and producer surplus). This framework has important policy implications for payers who wish to improve population health outcomes from constrained health care budgets. In particular, existing approaches to ‘value-based pricing’ should be reconsidered to ensure that patients receive a ‘fair’ share of the resulting economic surplus.

Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-023-01325-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:42:y:2024:i:2:d:10.1007_s40273-023-01325-z

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-023-01325-z

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().